CND Life Sciences, Beth Israel Ink Licensing Deal for Neurodegenerative Disease Test Technology
The agreement gives CND access to technologies key to CND's skin biopsy-based test for the hallmarks of the synucleinopathy family of neurodegenerative diseases.
Metabolon Partners With Swedish Biofinder 2 Study to Develop Dementia Biomarkers
The company will run metabolomics on cerebrospinal fluid and plasma from the study's baseline collections to identify biomarkers.
Amprion Wins Additional $730K NIH Grant to Validate Parkinson's Disease Test
The recently launched test is designed to detect a-synuclein aggregates to aid in the diagnosis of Parkinson's disease and other brain conditions.
Centogene, Alector Partner to ID Frontotemporal Dementia Patients With Genetic Mutations
The EFRONT study aims to enroll more than 3,000 FTD patients for genetic testing at centers in Belgium, Germany, Greece, Italy, Portugal, Spain, and Turkey.
CND Life Sciences Wins $2.4M NIH Grant to Develop Synucleinopathy Test
The test is designed to detect and visualize abnormal phosphorylated alpha-synuclein — a hallmark of synucleinopathies — in cutaneous nerve fibers.